Highlights
Intestinal Enterococcus domination following allogeneic hematopoietic cell transplantation correlates with heightened acute graft-versus-host disease (GVHD) mortality risk. Monocolonization with Enterococcus faecalis alone proves sufficient to induce major histocompatibility complex class II (MHC-II) expression in colonic epithelium of gnotobiotic mice. A lantibiotic-producing Blautia producta consortium prevents Enterococcus domination post-transplantation and significantly improves GVHD survival. These findings illuminate the Enterococcus-epithelium-MHC-II axis as a promising therapeutic target for preventing lethal GVHD.
Background: The Clinical Challenge of Acute GVHD
Allogeneic hematopoietic cell transplantation (allo-HCT) represents a potentially curative treatment strategy for patients with hematologic malignancies, including leukemias, lymphomas, and myelomas. Despite advances in transplant techniques and supportive care, acute graft-versus-host disease remains a formidable complication, contributing substantially to transplant-related morbidity and mortality. The gastrointestinal tract serves as a primary target organ in acute GVHD, with intestinal involvement representing a major source of clinical deterioration and treatment failure.
The intestinal ecosystem, comprising trillions of microorganisms collectively termed the gut microbiome, plays a critical role in maintaining mucosal homeostasis and modulating immune responses. Disruption of this delicate balance—termed dysbiosis—has emerged as a significant factor influencing transplant outcomes. Clinical observations have consistently demonstrated that intestinal domination by Enterococcus species following allo-HCT associates with increased mortality risk from acute GVHD, yet the precise mechanisms underlying this association have remained incompletely understood.
Major histocompatibility complex class II molecules, typically expressed on professional antigen-presenting cells such as dendritic cells and macrophages, play an essential role in presenting exogenous antigens to CD4+ T lymphocytes. While intestinal epithelial cells are generally MHC-II negative, pathological expression of MHC-II on these cells can trigger inappropriate immune activation against commensal flora and dietary antigens, potentially exacerbating inflammatory conditions including GVHD.
Study Design
This investigation employed a multi-pronged experimental approach combining an MHC-disparate mouse model of GVHD with gnotobiotic mouse systems to dissect the mechanistic relationship between Enterococcus colonization and intestinal MHC-II expression. The research team colonized gnotobiotic mice with specific bacterial species or defined consortia to evaluate their effects on colonic MHC-II expression independent of the complex native microbiome.
In the transplantation experiments, mice receiving allogeneic bone marrow and splenic T cells served as the GVHD model, with mortality and clinical scoring as primary endpoints. Colonization resistance against Enterococcus was evaluated through administration of a consortium containing lantibiotic-producing Blautia producta following allo-HCT. Flow cytometry and immunohistochemistry were employed to quantify MHC-II expression on intestinal epithelial cells, while immune cell populations from colonic lamina propria were characterized for inflammatory cytokine production.
Key Findings
The investigation revealed a compelling association between endogenous intestinal Enterococcus expansion and GVHD severity. In the MHC-disparate mouse model, mice exhibiting spontaneous Enterococcus outgrowth demonstrated significantly increased mortality compared to those maintaining Enterococcus colonization resistance, with heightened MHC-II expression observed on colonic epithelial cells.
Perhaps most notably, monocolonization of non-transplanted gnotobiotic mice with Enterococcus faecalis proved sufficient to induce robust colonic MHC-II expression. This finding indicates that E. faecalis alone, independent of the full microbial ecosystem or transplant-related factors, can drive MHC-II upregulation in intestinal epithelium—a mechanism with significant implications for understanding GVHD pathogenesis.
Specificity emerged as a critical feature of this phenomenon. Not all Enterococcus species induced MHC-II expression; select species within the genus failed to replicate the effect observed with E. faecalis. Furthermore, colonization with a consortium of four anaerobic commensal bacteria, including Blautia producta, did not affect colonic MHC-II expression, suggesting that the Enterococcus-induced pathway represents a specific rather than generalized response to bacterial colonization.
The functional consequences of E. faecalis-induced MHC-II expression extended to local immune populations. Colonization triggered inflammatory responses in both CD4+ T cells and natural killer cells isolated from the colonic lamina propria—the two principal cellular sources of interferon gamma, the cytokine driving MHC-II expression in non-professional antigen-presenting cells. This finding establishes a plausible mechanistic cascade connecting bacterial colonization to epithelial MHC-II upregulation through immune cell activation.
Building upon these mechanistic insights, the researchers explored therapeutic intervention through restoration of colonization resistance. Administration of a consortium containing lantibiotic-producing B. producta to transplanted mice prevented intestinal Enterococcus domination following allo-HCT. Critically, this bacterial intervention translated into improved GVHD survival, providing proof-of-concept for targeting the Enterococcus-epithelium-MHC-II axis as a viable preventive strategy.
Expert Commentary and Mechanistic Insights
The findings presented in this study illuminate a previously unrecognized pathway linking gut bacterial composition to GVHD severity through modulation of intestinal epithelial immune phenotype. The demonstration that E. faecalis monocolonization suffices to induce MHC-II expression in the absence of transplantation establishes this bacterial species as a primary driver rather than merely a correlate of adverse outcomes.
The specificity of the response—observed with E. faecalis but not other Enterococcus species or anaerobic commensals—suggests distinct molecular mechanisms underlying the interaction between specific bacterial taxa and intestinal epithelium. Lantibiotics, a class of ribosomally synthesized antimicrobial peptides produced by B. producta, appear to mediate competitive exclusion of Enterococcus, offering a mechanistic explanation for the protective effect of the bacterial consortium.
From a translational perspective, the therapeutic strategy of administering lantibiotic-producing commensals to restore colonization resistance represents an attractive approach to GVHD prevention. Unlike broad-spectrum antibiotics, which indiscriminately perturb the microbiome, targeted bacterial therapeutics aim to re-establish ecological relationships that protect against pathogen domination.
Several limitations warrant consideration when interpreting these findings. The studies were conducted in mouse models, and translation to human allo-HCT recipients requires validation in clinical cohorts. Additionally, the precise molecular signals from E. faecalis that trigger MHC-II expression remain to be fully characterized, and the relative contribution of epithelial MHC-II to overall GVHD pathology compared to other immune mechanisms requires further investigation.
Conclusion
This research delineates a novel mechanism by which Enterococcus faecalis aggravates graft-versus-host disease through induction of MHC-II expression on intestinal epithelial cells, activating local inflammatory responses mediated by CD4+ T cells and natural killer cells. The demonstration that lantibiotic-producing Blautia producta can prevent Enterococcus domination and improve survival provides a mechanistic rationale for microbiome-targeted therapeutic strategies in allo-HCT.
The Enterococcus-epithelium-MHC-II axis emerges as a promising target for intervention, potentially enabling prevention of lethal GVHD through restoration of beneficial microbial ecology. These findings advance understanding of host-microbiome interactions in the transplant setting and open avenues for developing microbiota-based interventions to improve outcomes for patients undergoing allogeneic hematopoietic cell transplantation.
Funding and Clinical Trial Registration
The study received support from institutional and grant funding sources. Specific funding details and clinical trial registration numbers can be found in the original publication (Blood, 2026;147(13):1485-1497; PMID: 41460962).
References
1. Nguyen CL, Funes J, Ghale R, et al. Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease. Blood. 2026;147(13):1485-1497. doi:10.1182/blood.2024026892. PMID: 41460962.
2. Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death after graft-versus-host disease. Clin Infect Dis. 2015;60(8):1185-1193.
3. Staffas A, Burgos da Silva M, van den Brink MRM. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood. 2017;129(8):927-935.
4. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(7):905-914.